Genetically modified major histocompatibility complex mice
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsLynn Macdonald, Andrew J. Murphy, Naxin Tu, Cagan Gurer, Vera Voronina, Sean Stevens
Life of this patent
Estimating the term…
Abstract
The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II α and β polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
Claims10
-34. (canceled)
A method of modifying an MHC II locus of a rodent to express a chimeric human/rodent MHC II complex comprising replacing at the endogenous rodent MHC II locus a nucleotide sequence encoding a rodent MHC II complex with a nucleotide sequence encoding a chimeric human/rodent MHC II complex.
-41. (canceled)
The method of claim 48, wherein the mouse MHC II α polypeptide is a mouse H-2E α polypeptide and the human MHC II a polypeptide is a human HLA-DR4 α polypeptide, and
- wherein the mouse MHC II β polypeptide is a mouse H-2E β polypeptide, and the human MHC II β polypeptide is a human HLA-DR4 β polypeptide.
Dependencies are inferred from the claim text.